<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5090659 Figure_1-A-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 1-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A) Box blot of vitrealANG-1 levels from newly diagnosed patients diagnosed with wAMD, DR, proliferative DR, and RVO compared to controls (macular whole). B) Box blot of vitrealANG-2 levels from patients as in A). The interquartile range of the data is indicated by the box. A non-parametric Kruskal-Wallis analysis (**, P = 0.029) followed by Dunn's method for multiple comparisons was used to show significant differences of the groups to control which are indicated by an asterisks. ANG-1 levels did not differ significantly, but ANG-2 levels were significantly different:control vs AMD (*, P = 0.0451), vs DR (*, P &lt; 0.0001), pDR (*,P &lt; 0.0001) and RVO (P &lt; 0.0001).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_1-D</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 1-D</infon>
    <infon key="sourcedata_figure_dir">Figure_1-D</infon>
    <passage>
      <offset>0</offset>
      <text>D) 24-h concentration of ANG-2 in supernatants of the basal site of the culture stimulated with 5 ng/ml of VEGF-A, 200 ng/ml of ANG-1 or the combination. Error bars show SEM with one sided ANOVA (****, P &lt; 0.0001) and Tukey's multiple T-test for five independent experiments indicating significance for control vs VEGF-A (**, P = 0.0028); VEGF-A vs ANG-1 (****, P &lt;0.0001); ANG-1 vs VEGF-A &amp; ANG1 (**, P = 0.0061); VEGF-A vs VEGF-A &amp; ANG-1 (ns, P = 0.0625).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_1-E</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 1-E</infon>
    <infon key="sourcedata_figure_dir">Figure_1-E</infon>
    <passage>
      <offset>0</offset>
      <text>E) Humanendothelial cells plated on filters were assessed for endothelial barrier function over time after addition of 5 ng/ml VEGF-A alone or in combination with 200 ng/ml ANG-1 or 10 &#956;g/ml anti-ANG-2 or all three test items. The final time point was used for statistical analysis. Error bars show SEM with one sided ANOVA (****, P &lt; 0.0001) and Tukey's multiple T-test for three independent experiments indicating significance of VEGF-A vs untreated (****, P &lt; 0.0001); vs VEGF-A &amp; ANG-1 &amp; anti-ANG-2 (***, P = 0.0004); vs VEGF-A &amp; anti-ANG-2 (P = 0.038); vs VEGF-A &amp; ANG-1, (P = 0.040). Furthermore, VEGF-A &amp; anti-ANG-2 &amp; ANG-1 is significantly different vs VEGF-A &amp; ANG-1 (*, P = 0.0451) and VEGF-A &amp; anti-ANG-2 (*, P = 0.0474) and untreated is significantly different from vs VEGF-A &amp; ANG-1 (*, P = 0.0009) and VEGF-A &amp; anti-ANG-2 (*, P = 0.0008).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_10-A</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 10-A</infon>
    <infon key="sourcedata_figure_dir">Figure_10-A</infon>
    <passage>
      <offset>0</offset>
      <text>A) VEGF-A levels only slightly increased from D16 to D30 in the IgG control. At D16 levels of IgG control are significantly higher compared to anti-VEGF-A (++++, P &lt; 0.0001); RG7716, 30 &#956;g (++++, P &lt; 0.0001) and RG7716, 90 &#956;g (++++, P &lt; 0.0001). Anti-ANG-2 levels are comparable to IgG control and therefore significantly different from anti-VEGF-A (++++, P &lt; 0.0001); RG7716, 30 &#956;g (++++, P &lt; 0.0001) and RG7716, 90 &#956;g (++++, P &lt; 0.0001). At D30 the levels of VEGF-A are significantly reduced in the RG7716, 90 &#956;g group are compared to IgG control (*, P = 0.0309). Anti-ANG-2 remains at levels comparable to IgG control and is therefore significantly higher than RG7716, 30 &#956;g (*, P = 0.0107), RG7716, 90 &#956;g (**, P = 0.002) and anti-VEGF-A (*, P = 0.0162).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_10-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 10-B</infon>
    <infon key="sourcedata_figure_dir">Figure_10-B</infon>
    <passage>
      <offset>0</offset>
      <text>B) ANG-2 levels increased from D16 to D30 in the IgG control. The same patterns, with a weaker total increase, were seen for the ANG-2 and both RG7716 treatment groups. ANG-2 levels were significantly higher at D16 in the anti-VEGF-A treated group compared to IgG control (++, P = 0.002), to anti-ANG-2 (+++, P = 0.0004), RG7716, 30 &#956;g (++++, P &lt; 0.0001) and RG7716, 90 &#956;g (++++, P &lt; 0.0001).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_10-C</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 10-C</infon>
    <infon key="sourcedata_figure_dir">Figure_10-C</infon>
    <passage>
      <offset>0</offset>
      <text>C) The reductions of treatments compared to IgG control at day 30 did not reach significance. IL-6 levels only very slightly increased from D16 to D30 in the IgG control; while for all other treatment groups there was a trend to reduced IL-6 levels at D30 compared to baseline with the high dose of RG7716 reaching significance, IgG control vs RG7716, 90 &#956;g (*, P = 0.023).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_10-D</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 10-D</infon>
    <infon key="sourcedata_figure_dir">Figure_10-D</infon>
    <passage>
      <offset>0</offset>
      <text>D) IL-8 levels increased from D16 to D30 in the IgG control group. Compared to the IgG control the levels of IL-8 were reduced in the anti-VEGF-A (*, P = 0.0262), RG7716, 30 &#956;g (*, P = 0.0188) and RG7716, 90 &#956;g (*, P = 0.0107) treatments at at D30.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_2-A-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 2-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A,B) Real-time qPCR analysis of ANG-2 levels in retina and RPE/choroid complexes of JR5558 and C57Bl/6J (C57) mice. A) Relative expression levels of ANG-2 were significantly increased in the RPE/choroid complexes of JR5558mice in comparison to C57, at 50 and 62 days old (P = 0.022 at D50 and P = 0.042 and at D62). B) By contrast, retina levels of ANG-2 were not significantly different between C57 and JR5558mice, indicating neovascularization is driven locally by ANG-2. SEM is shown as error bar with n = 4 animals per group. *Denotes statistical significance of JR5558mice compared to wild type C57bl6 using unpaired T-test for each time point analyzed separately.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_2-D-M</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 2-D-M</infon>
    <infon key="sourcedata_figure_dir">Figure_2-D-M</infon>
    <passage>
      <offset>0</offset>
      <text>D-I) Representative examples of fluorescence angiograms of IgG control (D), anti-VEGF-A (E), anti-ANG-2 (F) (all the 5 mg/kg) and three doses of anti-VEGF-A/ANG-2 (G,H,I), (at 3, 5, and 10 mg/kg). J,K) Bar graph of numbers of spontaneously occurring lesion number (J) and area by fluorescence angiography (K) after two weekly doses of antibody (antibodies at 5 mg/kg IP and anti-VEGF-A/ANG-2 at 10 [high], 5 [mid], and 3 [low] mg/kg IP) followed by analysis a week later in the early intervention model. L,M) Bar graph of numbers of spontaneously occurring lesion numbers (L) and area by fluorescence angiography (M) after two weekly doses of antibody (3 mg/kg IP) followed by analysis a week later in the late intervention model.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_3-A-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 3-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A) Bar graph showing the relative change in OCT-measured volume between the outer nuclear layer and the RPE layer following intervention with test articles. Anti-VEGF-A and anti-ANG-2 were given at 5 mg/kg and anti-VEGF-A/ANG-2 at 1, 5, and 10 mg/kg (low, mid, and high dose). B) Representative OCT images converted to heat maps with the scaling grade given on the right of the figure delineating fluid filled areas of the retina. Baseline (D46) and 14 days treatments of IgG control, anti-VEGF-A, anti-ANG-2, and bispecific anti-VEGF-A/ANG-2 at the end of the experiment (D60) are shown. For the region of interest, the corresponding FA image at D60 is also shown as comparator.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_4-A-G</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 4-A-G</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A-G</infon>
    <passage>
      <offset>0</offset>
      <text>A) Bar graph of number of IBA-1+cells in the retina of IgG control, anti-VEGF-A, anti-ANG-2 (all 5 mg/kg IP), and bispecific anti-VEGF-A/ANG-2 (at 10, 5, and 3 mg/kg)-treated mice in the late interference model at D60.B) IgG control, C) anti-VEGF-A, D) anti-ANG-2, E-G) anti-VEGF-A/ANG-2 low, mid and high: representative micrographs of whole-mount eyecup preparations stained with isolectin-B4-positive (green) to stain vessels and anti-IBA1 (red) to stain for macrophages show a decrease both in absolute numbers and clustering of subretinal IBA-1-expressing cells associated with neovascular complexes in anti-VEGF-A/ANG-2 treatment groups. Error bars show SEM with n = 6 animals per group (Scale bar, 200&#181;m). All significant differences are shown by * after one sided ANOVA (***, P &lt; 0.0008) and Tukey's multiple t-test. IgG control is significant against anti-VEGF-A/ANG-2 low (*, P &lt; 0.0134), -mid (**, P &lt; 0.0078) and -high (**, P &lt; 0.0042); furthermore anti-ANG-2 against anti-VEGF-A/ANG-2 mid (*, P &lt; 0.0353).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_5-A-G</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 5-A-G</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A-G</infon>
    <passage>
      <offset>0</offset>
      <text>A) Bar graph of TUNEL-positive cells in the retina of mice treated with 5 mg/kg anti-VEGF-A, anti-ANG-2, and 3, 5, and 10 mg/kg anti-VEGF-A/ANG-2. Error bars show SEM with n = 6 animals per group and * denote all significant changes after one sided ANOVA (**, P = 0.0041) and Tukey's multiple t-test. IgG control is significantly different from anti-VEGF-A/ANG-2 mid (**, P = 0.0077) and -high (**, P = 0.0028). B) IgG control, C) anti-VEGF-A, D) anti-ANG-2, E-G) anti-VEGF-A/ANG-2 low, mid, high: representative micrographs of whole-mount retinae preparations display the reduction of TUNEL-positive photoreceptor cells (green) clustered around focal neovascular lesions in anti-VEGF-A/ANG-2 (E-G) and, to a lesser extent, anti-VEGF-A- (C) and anti-ANG-2 (D)-treated groups compared with IgG-treated controls (B), scale bar 200 &#956;M.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_5-H-I</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 5-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_5-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>H) ERG was used to assess retinal function in response to large-field flash stimuli under both scotopic and photopic conditions. Representative photopic (light-adapted) and scotopic (dark-adapted) flash response series show increased amplitude and reduced latency after treatment with bispecific VEGF-A/ANG-2 compared with IgG control (both 3 mg/kg). ERG shows reduced depression of B-wave responses in JR5558mice treated with anti-VEGF-A/ANG-2 compared to IgG control. I) Maximum photopic ERG amplitude was increased using the rodent crossreactive bispecific VEGF-A/ANG-2 compared to single anti-VEGF-A or anti-ANG-2 treatments (all at 3 mg/kg). There was a significant increase in amplitude at stimuli &gt;2 log (cd*s/m2) between the bispecific VEGF-A/ANG-2 and IgG control group under scoptopic and phototopic conditions. *Denotes significance after ANOVA and Dunnett's multiple t-test compared to IgG control compared for each stimuli separately, error bars show SEM with n = 8 animals per group. Under phototopic conditions anti-VEGF-A/ANG-2 reached significance at 2.58 and 2.30 cd*s/m2 with P = 0.0498 and *P = 0.0479, respectively. Under scotopic conditions all stimuli reached significance for anti-VEGF-A/ANG-2 with P-values of -2.3 cd*s/m2 (P = 0.0498); -1.93 cd*s/m2 (P = 0.0035); -1.33 &amp; -1.03 cd*s/m2 (P &lt; 0.0001); -0.73 cd*s/m2 (P = 0.0002); -0.43 cd*s/m2, (P = 0.0004); -0.13 cd*s/m2, (P = 0.0024) and 0.18 cd*s/m2 (P = 0.0031). In addition anti-ANG-2 treatment reached significance at -0.13 cd*s/m2 (P = 0.011) and 0.18 cd*s/m2 (P = 0.005), respectively.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_6-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 6-B</infon>
    <infon key="sourcedata_figure_dir">Figure_6-B</infon>
    <passage>
      <offset>0</offset>
      <text>B) Summary table of experimental binding affinities of the parental components targeting VEGF-A (ranibizumab) and ANG-2 (LC10) as well as of RG7716 measured by isothermal titration calorimetry. RG7716 binds VEGF-A121 and -165 with an affinity comparable to ranibizumab (3.3 vs. 3.1 nM). ANG-2 binding of RG7716 is slightly decreased to 22 nM compared to &#945;-ANG-2 IgG1 (LC10) with 4.1 nM. No binding to ANG-1 was detectable for RG7716 or &#945;-ANG-2 IgG1 (LC10).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_6-C</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 6-C</infon>
    <infon key="sourcedata_figure_dir">Figure_6-C</infon>
    <passage>
      <offset>0</offset>
      <text>C) Inhibition of ANG-1 induced endothelial cell survival was tested in the presence of increasing concentrations of LC10 (anti-ANG-2 IgG, ANG-2 binding part in RG7716) and LC08 (ANG-1 and ANG-2 binding antibody). An average of three independent experiments is shown with SEM.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_6-D</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 6-D</infon>
    <infon key="sourcedata_figure_dir">Figure_6-D</infon>
    <passage>
      <offset>0</offset>
      <text>D) The ability of RG7716 to bind to ANG-2 and VEGF-A simultaneously and independent is demonstrated by a surface plasmon resonance experiment. RG7716 is captured via an anti-Fc antibody on the chip surface. The green curve depicts the experiment with ANG-2 in the first and VEGF-A in the second binding event. The red curve shows the binding events in the other sequence.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_7-A-E</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 7-A-E</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A-E</infon>
    <passage>
      <offset>0</offset>
      <text>Time-dependent binding of RG7716 is shown in pink, anti-VEGF-A/ANG-2 without modification of the Fc- part in red (wild-type), anti-VEGF-A/ANG-2 with modification of the FcRn binding site only in yellow (FcRn-), and anti-VEGF-A/ANG-2 with modification of the Fc&#947;R binding in grey (Fc&#947;R-). A) Shows SPR binding profile over time to immobilized Fc&#947;R-I, B) to immobilized Fc&#947;R-II, C) to immobilized Fc&#947;R-III, D) to immobilized FcRn. E) Summary data table of binding data for RG7716 in comparison to anti-VEGF-A/ANG-2 CrossMAbs without modifications in the Fc-part.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_8-A</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 8-A</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A</infon>
    <passage>
      <offset>0</offset>
      <text>A) Bar graph demonstrating platelet aggregation induced by complexes of heparin, VEGF-A165, and anti-VEGF-A (IgG1) in vitro using washed human platelets. Introduction of modification of the Fc-region in RG7716 does not allow platelet aggregation to happen as compared to anti-VEGF-A as wild type IgG1. All three components are needed as heparin/anti-VEGF-A alone does not activate platelet aggregation. Error bars show SEM of three independent experiments and **** denotes significance using ANOVA (P &lt; 0.0001) and Dunnett's multiple t-test comparing to IgG control with P &lt; 0.0001 of Heparin/VEGF-A/anti-VEGF-A against IgG control.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_8-B</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 8-B</infon>
    <infon key="sourcedata_figure_dir">Figure_8-B</infon>
    <passage>
      <offset>0</offset>
      <text>B) Kinetic presentation of mean serum, vitreous, and aqueous humor concentrations after single intravitreal administration of 0.5 mg of RG7716 in cynomolgus monkeys.</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_8-C</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 8-C</infon>
    <infon key="sourcedata_figure_dir">Figure_8-C</infon>
    <passage>
      <offset>0</offset>
      <text>C) Summary table of key experimental PK parameters of RG7716 and anti-VEGF-A/ANG-2-Fc&#947;R- (with intact FcRn binding).</text>
    </passage>
  </document>
  <document>
    <id>5090659 Figure_9-M</id>
    <infon key="sourcedata_document">2297</infon>
    <infon key="doi">10.15252/emmm.201505889</infon>
    <infon key="pmc_id">5090659</infon>
    <infon key="figure">Figure 9-M</infon>
    <infon key="sourcedata_figure_dir">Figure_9-M</infon>
    <passage>
      <offset>0</offset>
      <text>B) Inhibition of neovascularization measured in severity grades, change of severity from baseline is shown for each treatment; all treatment significantly reduced the severity grade compared to IgG control. In addition, efficacy of RG7716 (150 kDa molecule at 90 &#181;g) was significantly better at equal molar concentration of binding sites than anti-VEGF-A (ranibizumab, 50 kDa molecule at 30 &#181;g), anti-ANG-2 and the low dose of RG7716 (30 &#181;g). C-G) Representative figures of fluorescence fundusangiograms at day 28 and H-L) of cross sections of a hematoxylin staining of a spot at the end of the experiment from eyes treated with IgG control, anti-VEGF-A, anti-ANG-2 and RG7716 at 30 and 90 &#956;g, respectively.</text>
    </passage>
  </document>
</collection>
